A phase 2 study found micro-doses of latanoprost were consistent with standard drops in lowering IOP and were more likely to be successfully administered by subjects, Eyenovia announced in a press release.
Full results of the phase 2 PG21 study, which compared Eyenovia’s 0.4 µg piezo-print micro-dose of latanoprost with standard latanoprost eye drops, were recently published in Clinical Ophthalmology. The micro-dose uses 75% less drug and preservative, the release said.
Subjects using the micro-dose were successful at self-administering the drops 88% of the time compared with less
Uncategorized